Pfizer said Wednesday the Food and Drug Administration accepted for priority review its supplemental application seeking to expand the use of its prostate cancer treatment Talzenna in combination with ...
Bayer announced two new collaborations, one with Kairos Pharma on a prostate cancer therapy and another with Henry Ford Health on wider research across several diseases. The Kairos Pharma partnership ...
July 22 (Reuters) - Pfizer said on Wednesday the U.S. Food and Drug Administration has granted priority review to its ...
(NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) accepted for Priority Review a supplemental New Drug Application (sNDA) for TALZENNA ® (talazoparib), an oral poly ...
Novartis AG ended Q2 on a high note as oncology offset Entresto weakness; 2026 guidance reaffirmed. Read why NVS stock is ...
The TROG 08.03 RAVES randomized controlled trial substudy examined quality of life after post-prostatectomy radiation therapy.
Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company focused on overcoming cancer drug resistance, today announced a strategic collaboration with Bayer to evaluate ...
Prostate tumors can vanish from the immune system’s radar. Now, scientists have found a way to strip away that disguise by changing the length of a single RNA molecule.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results